212 related articles for article (PubMed ID: 19476653)
1. Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis.
Turashvili G; Leung S; Turbin D; Montgomery K; Gilks B; West R; Carrier M; Huntsman D; Aparicio S
BMC Cancer; 2009 May; 9():165. PubMed ID: 19476653
[TBL] [Abstract][Full Text] [Related]
2. Membrane connectivity estimated by digital image analysis of HER2 immunohistochemistry is concordant with visual scoring and fluorescence in situ hybridization results: algorithm evaluation on breast cancer tissue microarrays.
Laurinaviciene A; Dasevicius D; Ostapenko V; Jarmalaite S; Lazutka J; Laurinavicius A
Diagn Pathol; 2011 Sep; 6():87. PubMed ID: 21943197
[TBL] [Abstract][Full Text] [Related]
3. Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases.
Turbin DA; Leung S; Cheang MC; Kennecke HA; Montgomery KD; McKinney S; Treaba DO; Boyd N; Goldstein LC; Badve S; Gown AM; van de Rijn M; Nielsen TO; Gilks CB; Huntsman DG
Breast Cancer Res Treat; 2008 Aug; 110(3):417-26. PubMed ID: 17912629
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis.
Sun H; Kang EY; Chen H; Sweeney KJ; Suchko M; Wu Y; Wen J; Krishnamurthy S; Albarracin CT; Ding QQ; Foo WC; Sahin AA
Breast Cancer Res Treat; 2024 Jun; 205(2):403-411. PubMed ID: 38441847
[TBL] [Abstract][Full Text] [Related]
5. Effects of the change in cutoff values for human epidermal growth factor receptor 2 status by immunohistochemistry and fluorescence in situ hybridization: a study comparing conventional brightfield microscopy, image analysis-assisted microscopy, and interobserver variation.
Atkinson R; Mollerup J; Laenkholm AV; Verardo M; Hawes D; Commins D; Engvad B; Correa A; Ehlers CC; Nielsen KV
Arch Pathol Lab Med; 2011 Aug; 135(8):1010-6. PubMed ID: 21809992
[TBL] [Abstract][Full Text] [Related]
6. Image analysis of HER2 immunohistochemical staining. Reproducibility and concordance with fluorescence in situ hybridization of a laboratory-validated scoring technique.
Minot DM; Voss J; Rademacher S; Lwin T; Orsulak J; Caron B; Ketterling R; Nassar A; Chen B; Clayton A
Am J Clin Pathol; 2012 Feb; 137(2):270-6. PubMed ID: 22261453
[TBL] [Abstract][Full Text] [Related]
7. Fully automated fluorescent in situ hybridization (FISH) staining and digital analysis of HER2 in breast cancer: a validation study.
van der Logt EM; Kuperus DA; van Setten JW; van den Heuvel MC; Boers JE; Schuuring E; Kibbelaar RE
PLoS One; 2015; 10(4):e0123201. PubMed ID: 25844540
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of analytical accuracy of HER2 status in patients with breast cancer: Comparison of HER2 GPA with HER2 IHC and HER2 FISH.
Jensen SG; Thomas PE; Christensen IJ; Balslev E; Hansen A; Høgdall E
APMIS; 2020 Nov; 128(11):573-582. PubMed ID: 32860265
[TBL] [Abstract][Full Text] [Related]
9. HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques.
Ellis CM; Dyson MJ; Stephenson TJ; Maltby EL
J Clin Pathol; 2005 Jul; 58(7):710-4. PubMed ID: 15976337
[TBL] [Abstract][Full Text] [Related]
10. Free digital image analysis software helps to resolve equivocal scores in HER2 immunohistochemistry.
Helin HO; Tuominen VJ; Ylinen O; Helin HJ; Isola J
Virchows Arch; 2016 Feb; 468(2):191-8. PubMed ID: 26493985
[TBL] [Abstract][Full Text] [Related]
11. Computer Aided Semi-Automated Evaluation of HER2 Immunodetection--A Robust Solution for Supporting the Accuracy of Anti HER2 Therapy.
Micsik T; Kiszler G; Szabó D; Krecsák L; Hegedűs C; Tibor K; Molnár B
Pathol Oncol Res; 2015 Sep; 21(4):1005-11. PubMed ID: 25788005
[TBL] [Abstract][Full Text] [Related]
12. Comparison of visual and automated assessment of HER2 status and their impact on outcome in primary operable invasive ductal breast cancer.
Mohammed ZM; Going JJ; McMillan DC; Orange C; Mallon E; Doughty JC; Edwards J
Histopathology; 2012 Oct; 61(4):675-84. PubMed ID: 22747525
[TBL] [Abstract][Full Text] [Related]
13. Interobserver Variation in the Assessment of Immunohistochemistry Expression Levels in HER2-Negative Breast Cancer: Can We Improve the Identification of Low Levels of HER2 Expression by Adjusting the Criteria? An International Interobserver Study.
Baez-Navarro X; van Bockstal MR; Nawawi D; Broeckx G; Colpaert C; Doebar SC; Hogenes MCH; Koop E; Lambein K; Peeters DJE; Sinke RHJA; Bastiaan van Brakel J; van der Starre-Gaal J; van der Vegt B; van de Vijver K; Vreuls CPH; Vreuls W; Westenend PJ; van Deurzen CHM
Mod Pathol; 2023 Jan; 36(1):100009. PubMed ID: 36788064
[TBL] [Abstract][Full Text] [Related]
14. Institutional quality assurance for breast cancer HER2 immunohistochemical testing: identification of outlier results and impact of simultaneous fluorescence in situ hybridization cotesting.
Green IF; Zynger DL
Hum Pathol; 2015 Dec; 46(12):1842-9. PubMed ID: 26412217
[TBL] [Abstract][Full Text] [Related]
15. AutoIHC-Analyzer: computer-assisted microscopy for automated membrane extraction/scoring in HER2 molecular markers.
Tewary S; Arun I; Ahmed R; Chatterjee S; Mukhopadhyay S
J Microsc; 2021 Jan; 281(1):87-96. PubMed ID: 32803890
[TBL] [Abstract][Full Text] [Related]
16. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
Akhdar A; Bronsard M; Lemieux R; Geha S
Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
[TBL] [Abstract][Full Text] [Related]
17. A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility.
Powell WC; Hicks DG; Prescott N; Tarr SM; Laniauskas S; Williams T; Short S; Pettay J; Nagle RB; Dabbs DJ; Scott KM; Brown RW; Grogan T; Roche PC; Tubbs RR
Appl Immunohistochem Mol Morphol; 2007 Mar; 15(1):94-102. PubMed ID: 17536315
[TBL] [Abstract][Full Text] [Related]
18. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of HER2 status in breast carcinoma using fully automated HER2 staining and fluorescence in-situ hybridization technology].
Ying JM; Liu XY; Guo L; Xie YQ; Lü N
Zhonghua Bing Li Xue Za Zhi; 2012 May; 41(5):296-300. PubMed ID: 22883666
[TBL] [Abstract][Full Text] [Related]
20. Concordance of HER2-low scoring in breast carcinoma among expert pathologists in the United Kingdom and the republic of Ireland -on behalf of the UK national coordinating committee for breast pathology.
Zaakouk M; Quinn C; Provenzano E; Boyd C; Callagy G; Elsheikh S; Flint J; Millican-Slater R; Gunavardhan A; Mir Y; Makhija P; Di Palma S; Pritchard S; Tanchel B; Rakha E; Atallah NM; Lee AHS; Pinder S; Shaaban AM
Breast; 2023 Aug; 70():82-91. PubMed ID: 37419078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
